Systematic review: Potential preventive effects of statins against oesophageal adenocarcinoma

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 4, 2012, Pages 301-311

  Alexandre, L ^a   Clark, A B ^a   Cheong, E ^b   Lewis, M P N ^b   Hart, A R ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; RAC PROTEIN; RAS PROTEIN; SIMVASTATIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER PREVENTION; CANCER PROGNOSIS; CARCINOGENESIS; CELL SURVIVAL; CELL VIABILITY; CHOLESTEROL SYNTHESIS; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; EFFECT SIZE; ESOPHAGEAL ADENOCARCINOMA; FUNCTIONAL ASSESSMENT; HUMAN; HYDROPHILICITY; LIPOPHILICITY; METASTASIS POTENTIAL; PRENYLATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ADENOCARCINOMA; ESOPHAGEAL NEOPLASMS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84863990191     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05194.x     Document Type: Review

References (64)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D., Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Steevens J, Botterweck AA, Dirx MJ, van den Brandt PA, Schouten LJ,. Trends in incidence of oesophageal and stomach cancer subtypes in Europe. Eur J Gastroenterol Hepatol 2010; 22: 669-78.
3. Cook MB, Chow WH, Devesa SS,. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer 2009; 101: 855-9.
4. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr,. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-9.
5. Devesa SS, Blot WJ, Fraumeni JF Jr,. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-53.
6. Lepage C, Rachet B, Jooste V, Faivre J, Coleman MP,. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol 2008; 103: 2694-9.
7. Brown LM, Devesa SS, Chow WH,. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008; 100: 1184-7.
8. Falk J, Carstens H, Lundell L, Albertsson M,. Incidence of carcinoma of the oesophagus and gastric cardia. Changes over time and geographical differences. Acta Oncol 2007; 46: 1070-4.
9. Mariette C, Balon JM, Piessen G, et al,. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 2003; 97: 1616-23.
10. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE,. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27: 5062-7.
11. Haggitt RC,. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994; 25: 982-93.
12. Sharma P, McQuaid K, Dent J, et al,. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004; 127: 310-30.
13. Spechler SJ, Goyal RK,. Barrett's esophagus. N Engl J Med 1986; 315: 362-71.
14. Lagergren J, Bergstrom R, Lindgren A, Nyren O,. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31.
15. Kahrilas PJ,. Clinical practice. Gastroesophageal reflux disease. N Engl J Med 2008; 359: 1700-7.
16. Whiteman DC, Sadeghi S, Pandeya N, et al,. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 2008; 57: 173-80.
17. Abnet CC, Freedman ND, Hollenbeck AR, et al,. A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur J Cancer 2008; 44: 465-71.
18. Vaughan TL, Davis S, Kristal A, Thomas DB,. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 1995; 4: 85-92.
19. Ranka S, Gee JM, Johnson IT, et al,. Non-steroidal anti-inflammatory drugs, lower oesophageal sphincter-relaxing drugs and oesophageal cancer. A case-control study. Digestion 2006; 74: 109-15.
20. Lagergren J, Bergstrom R, Adami HO, Nyren O,. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 2000; 133: 165-75.
21. Vaughan TL, Farrow DC, Hansten PD, et al,. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev 1998; 7: 749-56.
22. Fortuny J, Johnson CC, Bohlke K, et al,. Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers. Clin Gastroenterol Hepatol 2007; 5: 1154-9 e3.
23. Alexandre L, Broughton T, Loke Y, Beales IL,. Meta-analysis: risk of esophageal adenocarcinoma with medications which relax the lower esophageal sphincter. Dis Esophagus 2011; DOI: 10.1111/j.1442-2050.2011.01285.x.
24. Abnet CC, Freedman ND, Kamangar F, et al,. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer 2009; 100: 551-7.
25. Ogunwobi OO, Beales IL,. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 2008; 103: 825-37.
26. Sadaria MR, Reppert AE, Yu JA, et al,. Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells. J Thorac Cardiovasc Surg 2011; 142: 1152-60.
27. Konturek PC, Burnat G, Hahn EG,. Inhibition of Barret's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins. J Physiol Pharmacol 2007; 58 (Suppl. 3): 141-8.
28. Hippisley-Cox J, Coupland C,. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010; 340: c2197.
29. Kaye JA, Jick H,. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004; 90: 635-7.
30. Nguyen DM, Richardson P, El-Serag HB,. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 2010; 138: 2260-6.
31. Vinogradova Y, Coupland C, Hippisley-Cox J,. Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer 2011; 11: 409.
32. Kastelein F, Spaander MC, Biermann K, et al,. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology 2011; 141: 2000-8.
33. Bhutta H, Clark A, Holt S, Lewis M, Hart A,. Oesophageal cancer-an aetiological investigation into the potential protective effect of statins in the UK general practice research database (GPRD). Gut 2011; 60: A36-7.
34. Nguyen DM, El-Serag HB, Henderson L, et al,. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2009; 7: 1299-304.
35. Friedman GD, Flick ED, Udaltsova N, et al,. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008; 17: 27-36.
36. Hill AB,. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300.
37. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG,. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 2007; 6: 541-55.
38. Goldstein JL, Brown MS,. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30.
39. Zhang FL, Casey PJ,. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996; 65: 241-69.
40. Cho SJ, Kim JS, Kim JM, et al,. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer 2008; 123: 951-7.
41. Kaneko R, Tsuji N, Asanuma K, et al,. Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer. J Biol Chem 2007; 282: 19273-81.
42. Kodach LL, Bleuming SA, Peppelenbosch MP, et al,. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway. Gastroenterology 2007; 133: 1272-81.
43. Nubel T, Dippold W, Kleinert H, Kaina B, Fritz G,. Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. FASEB J 2004; 18: 140-2.
44. Paragh G, Foris G, Paragh G Jr, et al,. Different anticancer effects of fluvastatin on primary hepatocellular tumors and metastases in rats. Cancer Lett 2005; 222: 17-22.
45. Zhang W, Wu J, Zhou L, Xie HY, Zheng SS,. Fluvastatin, a lipophilic statin, induces apoptosis in human hepatocellular carcinoma cells through mitochondria-operated pathway. Indian J Exp Biol 2010; 48: 1167-74.
46. Kusama T, Mukai M, Iwasaki T, et al,. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res 2001; 61: 4885-91.
47. Muller C, Bockhorn AG, Klusmeier S, et al,. Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. Int J Oncol 1998; 12: 717-23.
48. Mistafa O, Stenius U,. Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells. Biochem Pharmacol 2009; 78: 1115-26.
49. Ghosh PM, Ghosh-Choudhury N, Moyer ML, et al,. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. Oncogene 1999; 18: 4120-30.
50. Bouterfa HL, Sattelmeyer V, Czub S, et al,. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Res 2000; 20: 2761-71.
51. Zhong WB, Wang CY, Chang TC, Lee WS,. Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology 2003; 144: 3852-9.
52. Shibata MA, Ito Y, Morimoto J, Otsuki Y,. Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis 2004; 25: 1887-98.
53. Hanai J, Doro N, Sasaki AT, et al,. Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein Kinase (MAPK) and Phosphatidylinositol-3-kinase (PI3K)/AKT pathways. J Cell Physiol 2012; 227: 1709-20.
54. Sanli T, Liu C, Rashid A, et al,. Lovastatin sensitizes lung cancer cells to ionizing radiation: modulation of molecular pathways of radioresistance and tumor suppression. J Thorac Oncol 2011; 6: 439-50.
55. Fromigue O, Hay E, Modrowski D, et al,. RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ 2006; 13: 1845-56.
56. Cafforio P, Dammacco F, Gernone A, Silvestris F,. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 2005; 26: 883-91.
57. Roland CL, Harken AH, Sarr MG, Barnett CC Jr,. ICAM-1 expression determines malignant potential of cancer. Surgery 2007; 141: 705-7.
58. Lin YC, Shun CT, Wu MS, Chen CC,. A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clin Cancer Res 2006; 12: 7165-73.
59. Hayes SH, Seigel GM,. Immunoreactivity of ICAM-1 in human tumors, metastases and normal tissues. Int J Clin Exp Pathol 2009; 2: 553-60.
60. Lindblad M, Rodriguez LA, Lagergren J,. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Control 2005; 16: 285-94.
61. Palser T, Cromwell D, van der Meulen J, et al,. National Oesophago-Gastric Cancer Audit. The NHS information centre, 2009. Report No.: IC23090209.
62. Mihos CG, Santana O,. Pleiotropic effects of the HMG-CoA reductase inhibitors. Int J Gen Med 2011; 4: 261-71.
63. Boudreau DM, Yu O, Johnson J,. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 2010; 9: 603-21.
64. Moayyedi P, Burch N, Akhtar-Danesh N, et al,. Mortality rates in patients with Barrett's oesophagus. Aliment Pharmacol Ther 2008; 27: 316-20.